NFE2L2 and cancer: The major challenge in potential novel treatment approaches blocking NRF2 in cancer and especially in malignant gliomas will be to overcome expected severe negative side effects in residual cells, most probably neurons and muscle cells, which both may rapidly suffer from a decreased capacity to deal with high ROS levels, thereby being at risk to develop secondary neurodegenerative or myopathic symptoms.